ORKA Oruka Therapeutics, Inc. Insider Trading

CMO Joana Goncalves sold 7,000 shares ($603.9K) via 10b5-1 plan; retains 32.7K shares + derivative holdings of 372,555.

Joana Goncalves, Chief Medical Officer at Oruka Therapeutics, completed four separate sales totaling 7,000 shares for $603,937.77 on 2026-07-15, executed at prices ranging from $84.36 to $87.25 (blended $86.28). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. Post-sale, Goncalves retains 32.7K non-derivative shares and 372,555 shares through derivative securities (options and warrants), maintaining a meaningful stake in the company. The sale represents a 17.6% reduction in her non-derivative holdings, but occurs against the backdrop of a company with zero latest-quarter revenue and a $-31.8M net loss over the most recent full fiscal year, combined with a 52-week stock range of $12.84–$97.78. The stock has appreciated 25.8% over the prior 30 days and 29.2% over 90 days, positioning the insider's blended sale price ($86.28) well within the recent strength zone, though below the 52-week high of $97.78.

SVP Finance Arjun Agarwal sells 10.0K shares for $846.2K via scheduled 10b5-1 plan at ORKA; retains 101,459 and 61,250 option shares.

Arjun Agarwal, Senior Vice President of Finance, executed 4 separate sales totaling 9,999 shares for $846.2K on 2026-07-13 under a pre-arranged 10b5-1 trading plan, meaning this is a scheduled, non-discretionary transaction. His non-derivative holdings fell from 25.3K to 15.3K shares, but he retains 101,459 and 61,250 employee stock options, so his overall equity stake remains substantial. The stock trades at $84.56, having gained 21.0% over 30 days and 26.1% over 90 days from lows of $12.84, placing it -13.5% from a 52-week high of $97.78. The company reported $0.00 in revenue and a net loss of $-31.8M in its latest period, underpinning a $5.1B market cap despite unprofitability—a data point investors should weigh against the recent price momentum.

Director Fairmount Funds sold 3,553,410 shares (75.8% reduction) at $84.43 on 2026-07-01 for $300.0M; retains 1.13M shares plus derivative holdings.

Fairmount Funds Management LLC, a director of Oruka Therapeutics, executed a substantial sale of 3,553,410 shares at $84.43, reducing its direct equity stake by 75.8% while retaining 1,131,954 common shares and 94,497 Series B Preferred shares via derivative holdings. The company is unprofitable (net income of $-31,820,000 in the most recent fiscal period, with revenue of $0.00 in the latest quarter) and trades at a market cap of $5,626,515,902.29—a biotech-stage enterprise without near-term commercial revenue. The transaction price of $84.43 sits notably below the current price of $93.29 and the 52-week high of $97.78, indicating the sale occurred before the stock's recent 69.6% gain over 30 days and 75.0% gain over 90 days. Across the insider's full cross-ticker trading history, prior sells averaged -3.9% returns over 30 days but +12.3% over 90 days, with a 0.00% well-timed rate, suggesting a pattern where this insider's stock sales have not preceded downturns. The large size, majority-stake reduction, and post-transaction stock appreciation merit attention to whether additional insiders or directors execute similar transactions or if material developments have emerged since July 2026.

SVP Finance Agarwal sells 9,459 shares at $69.72 avg for $659.5K under 10b5-1 plan at unprofitable biotech

Arjun Agarwal, Senior Vice President Finance at Oruka Therapeutics, executed 3 separate sales totaling 9,459 shares for $659,507.59 at blended average price $69.72 on 2026-06-12. The transaction was conducted under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. His holdings reduced from 26,753 shares to 17,294 shares post-transaction. The company reported $0.00 revenue in its latest quarter with a net loss of $-31,820,000.00, and remains unprofitable. The stock currently trades at $68.86, near the transaction prices but down 24.3% from its 52-week high of $91.00. Prior trades by Agarwal at this same ticker (4 sales on 2026-05-18) lack measurable 30-day and 90-day outcomes.

Director Carl Dambkowski sold 35,000 ORKA shares ($2.5M) via 10b5-1 plan; retains 38,743 shares post-sale.

Director Carl Dambkowski executed 2 separate sales totaling 35,000 shares for $2,454,382.15 on 2026-06-11 and 2026-06-12 at an average price of $70.13, reducing his stake by approximately 47.5%. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled rather than discretionary. Oruka Therapeutics posted $0.00 revenue in its latest quarter with a net loss of $-31,820,000.00 and was unprofitable over its most recent full fiscal year. The current stock price of $69.89 is -23.2% from the 52-week high of $91.00, though the 30-day change shows +10.6% and the 90-day change shows +74.7%, indicating recent price recovery from earlier lows.

Director Carl Dambkowski sold 105,000 shares for $6.2M via 10b5-1 plan; stock down 13.0% in 30 days.

Carl Dambkowski, Director at Oruka Therapeutics, executed three separate sales totaling 105,000 shares (105.0K shares) for $6,191,366.32 ($6.2M) at a blended average price of $58.97 on 2026-05-21, reducing his holdings by 58.7% from 178,743 to 73,743 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The stock has declined 13.0% over the prior 30 days and trades at $60.61, down 33.4% from its 52-week high of $91.00, in a context where the company generated zero revenue in its latest quarter and posted a net loss of $31,820,000 ($-31.8M). Investors should note that while the director's cross-ticker track record shows an average 90-day return of +13.4% following prior sells, that success pattern reflects other holdings and does not address directional conviction at this ticker in particular.

SVP Agarwal sells 10,290 shares of ORKA for $607.8K in 4 scheduled transactions under 10b5-1 plan

Arjun Agarwal, Senior Vice President of Finance, executed 4 separate sales on 2026-05-18 totaling 10,290 shares for $607,806.41 at a blended average price of $59.07. This transaction was executed under a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. Post-transaction, Agarwal holds 16,406 shares, down from 26,696 shares, representing a 38.5% reduction in his holdings. The stock trades at $58.34, down 35.9% from its 52-week high of $91.00, and the company posted $0.00 revenue in the latest quarter with a net loss of $31.8M, indicating ongoing unprofitability. The scheduled nature of this filing precludes attribution of timing intent to the insider.

Venrock Healthcare (10% owner) bought 122,882 shares across 5 transactions totaling $1,407,367.87 at blended average $11.45; stock now $9.56.

Venrock Healthcare Capital Partners III, L.P., a 10% shareholder, executed 5 separate purchases totaling 122,882 shares for $1,407,367.87 between February 10–14, 2025, at prices ranging from $10.90 to $11.86 (blended average $11.45). The stock has since declined to $9.56, -68.6% from its 52-week high of $30.49 and down -18.6% in the 30-day period. Oruka Therapeutics posted zero revenue in the latest quarter and a net loss of $28,623,000.00 for the fiscal year. This purchase increases Venrock's holdings by 122,882 shares (+3.1%) to 4,148,428 shares, but the timing relative to the stock's -56.0% 90-day decline and the company's unprofitable operating position places this accumulation into a deteriorating context rather than a signal of confidence.

10% owner Janus Henderson buys 5,818 shares of ABIO at $2.93–$2.98 for $17,066.77; extends recent buying pattern

Janus Henderson, a 10% owner, completed 2 separate purchases totaling 5,818 shares (5.8K shares) for $17,066.77 on 2024-08-16 at prices of $2.93 and $2.98 per share, raising its post-transaction holdings to 2,117,213 shares (2.12M shares). This buy follows four prior purchases at the same ticker within the preceding 3 weeks (2024-07-24 and 2024-07-25), with only one of those five recent same-ticker trades measurable at 90 days and showing a +876.9% return. The current stock price of $44.04 is 30-day +11.7% and 90-day +12.9%, a substantial appreciation from the $2.93–$2.98 transaction prices. However, the company remains unprofitable with net income of $-2,678,000 and $0.00 in latest-quarter revenue, and Janus Henderson's cross-ticker track record shows its 13 prior buys averaged a 30-day return of +911.4%, establishing a high bar for market outperformance. The rapid-fire accumulation pattern and the sharp stock appreciation since purchase suggest the market has responded favorably, though the fundamental metrics remain a material constraint on baseline valuation.

Janus Henderson (10% owner) bought 220,083 shares at $3.18 avg on ABIO in four transactions for $699,165.11

Janus Henderson executed 4 separate purchases totaling 220,083 shares for $699,165.11 between July 24–25, 2024, at a blended average price of $3.18—representing an 11.6% increase to its holdings at ABIO. This accumulation occurs at prices 21.5% below the 52-week high of $48.00 and follows a sequence of five prior buys at this ticker within days (July 8–11), suggesting sustained acquisition activity. The company remains unprofitable (net income $-2,009,000.00 for the latest quarter and negative full-year earnings), and the stock has declined 9.5% over 30 days and 12.3% over 90 days from the transaction date. The timing context is critical: Janus Henderson's cross-ticker track record shows 9 prior buys, but none of the 5 prior ABIO transactions yet have measurable 90-day outcomes, making it premature to assess execution quality at this specific ticker.